JBLab (Cheil Vascular Research Institute)
enhance the health and quality of life of patients with cardiovascular diseases
through valuable studies and education


The publications listed within this section represent a sampling of scientific papers, abstracts and presentations that JBLab
Faculty have authored and that are the direct result of clinical research conducted at JBLab.

  • Kim SY, Joo SJ, Shin MS, Kim C, Cho EJ, Sung KC, Kang SM, Kim DS, Lee SH, Hwang KK, Park JB. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension. Medicine. 2016 May 1;95(22):e3764.
  • Shin MS, Kang DR, Kim C, Cho EJ, Sung KC, Kang SM, Kim DS, Joo SJ, Lee SH, Hwang KK, Park JB. Fimasartan for Independent Reduction of Blood Pressure Variability in Mild-to-Moderate Hypertension. Drug Des Devel Ther. 2016:10 1573?1580
  • Park JB, Shin JH, Kim DS, Youn HJ, Park SW, Shim WJ, Park CG, Kim DW, Lee HY, Choi DJ, Rim SJ, Lee SY, Kim JH; FOCUS Investigators.. Safety of the up-titration of nifedipine GITS and valsartan or low-dose combination in uncontrolled hypertension: the FOCUS study Clin Ther. 2016 Apr;38(4):832-42.
  • Jae SY, Bunsawat K, Fadel PJ, Fernhall B, Choi YH, Park JB, Franklin BA. Attenuated Heart Rate Recovery After Exercise Testing and Risk of Incident Hypertension in Men. American Journal of Hypertension. 2016 Apr 1:hpw028. (SCI IF. 3.402)
  • Lee HY, Kim YJ, Ahn T, Youn HJ, Chae SC, Seo HS, Kim KS, Rhee MY, Choi DJ, Kim JJ, Chun KJ. Yoo BS, Park JS, Oh SK, Kim DS, Kwan J, Ahn Y, Bae Park J, Jeong JO, Hyon MS, Cho EJ, Han KR, Kim DI, Joo SJ, Shin JH, Sung KC, Jeon ES. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3× 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. Clinical therapeutics. 2015 Nov 1;37(11):2581-96.
Go first 1 2 3 4 5 6 7 8 9 10 Go next Go last